# Haem.io - Executive Summary
## AI-Powered Diagnostic System for Blood Cancers

**Confidential - November 2025**

---

## ğŸ¯ The Opportunity

**Seeking:** Â£750,000 seed investment  
**Valuation:** Â£3-4M pre-money  
**Use of Funds:** 18-month runway to UKCA certification and first NHS sales  
**Target Close:** Q1 2026

---

## ğŸ©¸ The Problem

Blood cancer diagnosis is facing a crisis:

- **Data Chaos**: Haematologists manually extract critical genetic markers from multiple unstructured reports (cytogenetics, flow cytometry, molecular data) before diagnosis can even begin
- **Overwhelming Complexity**: Modern WHO 2022 and ICC 2022 guidelines contain hundreds of interconnected diagnostic pathwaysâ€”too complex for consistent human application
- **Life-or-Death Delays**: Current diagnosis takes days to weeks. Blood cancer cells can double in 24 hours. Every delay is potentially fatal.

> *"Accurate diagnosis forms the absolute bedrock of effective therapy"*  
> â€” Dr. John Chadwick, The Christie NHS Foundation Trust

Smaller NHS trusts lack specialist expertise and must outsource to 5 specialist centers at great cost and delay.

---

## ğŸ’¡ Our Solution

Haem.io is the **only end-to-end AI diagnostic system** for blood cancers:

1. **AI Extraction**: Advanced LLMs extract structured data from any report format (PDFs, scanned docs, text files)
2. **Logic Engine**: Formal decision trees based on WHO 2022 and ICC 2022 guidelines deliver precise classification
3. **Human-in-the-Loop**: AI extracts what it can, logic engines run diagnostic pathways, and we ask clinicians for additional information only when neededâ€”minimal input, maximum accuracy
4. **Complete Diagnostic Pipeline**: Not just diagnosisâ€”we deliver treatment recommendations, clinical trial matching, risk stratification (ELN, IPSS), and follow-up planning

**Time to diagnosis:** ~2 minutes (vs. days/weeks)

### Why We're Different

| Traditional Approach | Pure AI Solutions | Haem.io |
|---------------------|-------------------|---------|
| Manual data extraction | Black box decisions | AI + formal logic |
| Hours of clinician time | No explainability | Transparent reasoning |
| Error-prone | Inconsistent | Validated pathways |
| Days to diagnosis | Can't be certified | Medical device certified |

**Zero integration friction:** Works with existing hospital systemsâ€”no IT integration required.

---

## ğŸ“Š Market Opportunity

### Immediate Market (Blood Cancers)
- **1.2M annual global diagnoses** (conservativeâ€”many undiagnosed in lower-income countries)
- **40,000+ UK diagnoses/year**
- **3rd most fatal cancer in UK**
- Every single diagnosis needs fast, accurate pathways

### Addressable Market Expansion
- **Phase 1** (2026-2028): Acute Myeloid Leukemia (AML) - Most complex blood cancer
- **Phase 2** (2028-2030): All blood cancers (MDS, lymphomas, multiple myeloma)
- **Phase 3** (2030+): All cancers - As oncology moves toward genetics-driven diagnosis

### Market Tailwinds
- **Â£120B** - AI in Healthcare market by 2030 (49.1% CAGR)
- **Â£30B** - AI in Diagnostics market by 2034 (37.6% CAGR)
- **Â£20M** - NHS AI Diagnostic Fund (cancer, stroke, heart disease focus)

*Sources: GlobeNewswire 2025, Gov.uk 2023*

---

## ğŸš€ Traction & Validation

### NHS Pilot Studies (Active)
- âœ… **Manchester Foundation Trust** - In process of ethical approval
- âœ… **The Christie NHS Foundation Trust** - Kickoff stage with Prof. John Chadwick
- âœ… **UK AML Research Network** - Signed letter of intent for pilot study validation

### Major Grant Inclusion
- âœ… **Â£7M UK National AML Relapse Study** - Invited to integrate Haem.io into national research program

### Clinical Endorsements

> *"Haem.io offers the potential to standardise complicated cases and provide patients with a good quality diagnosis before commencing treatment."*  
> â€” **Dr. Tom Coats**, Royal Devon & Exeter NHS Trust

> *"I believe Haem.io has the potential to revolutionise the quality of care that patients receive."*  
> â€” **Dr. John Chadwick**, The Christie NHS Foundation Trust

> *"The UK AML Research Network is committed to participate in a future pilot study to help validate the platform's clinical utility."*  
> â€” **Prof. Charles Craddock**, Chair, UK AML Research Network

---

## ğŸ‘¥ The Team

### Founders

**Robert Edward Lee** - CEO & Founder  
- Computer Science background, FinTech AI experience
- Leading software development and business strategy
- Former lymphoma patientâ€”personal mission

**Dr. Daniel Clarke** - Data & Analytics Lead  
- PhD Nuclear Physics (University of Manchester, CERN)
- Leading technology and platform architecture
- Advanced analytics and AI/ML expertise

**Dr. John Burthem** - Co-CMO & Clinical Lead  
- Lead Haematology Diagnostician, Manchester Foundation Trust
- Clinical logic development and validation
- 20+ years NHS haematology experience

**Dr. Luke Carter-Brzezinski** - Co-CMO & Clinical Strategy  
- Practicing NHS haematologist
- Clinical outreach, demonstrations, pilot deployment
- Clinical strategy and validation oversight

### Competitive Advantage

**Domain expertise as moat:** Our haematologist co-founders encode years of specialist knowledge into validated decision trees. Extremely difficult to replicate without this depth of clinical expertise embedded in the team.

---

## ğŸ’° Business Model

### Revenue Streams

**Primary: SaaS Licensing**
- NHS Trusts: Â£50-100k/year
- Private Hospitals: Â£75-150k/year
- Diagnostic Labs: Â£100-200k/year

**Secondary: Diagnostic Service**
- Outsourced diagnostic desk for smaller/private hospitals
- Â£1,000-1,500 per case
- 48-hour turnaround (vs. weeks at traditional centers)
- Target: 10-20 cases/month initially = Â£120-360k/year

### Unit Economics
- **CAC**: Â£15-25k per trust (sales effort + pilot costs)
- **LTV**: Â£50k Ã— 5 years = Â£250k minimum
- **LTV:CAC ratio**: 10:1

---

## ğŸ“ˆ Financial Projections

| Year | Period | Milestone | Revenue | Net P/L |
|------|--------|-----------|---------|---------|
| **Year 1** | 2026 | Pilots & validation | Â£0 | -Â£540k |
| **Year 2** | 2027 | UKCA approval, Q4: 2-3 trusts signed | Â£0* | -Â£300k |
| **Year 3** | 2028 | 10 NHS + 2 UK private hospitals | Â£700k | **+Â£40k** |
| **Year 4** | 2029 | 15 NHS + Middle East + 3 labs | Â£2.4M | **+Â£1.2M** |
| **Year 5** | 2030 | 20 NHS + Malaysia + GCC | Â£5.6M | **+Â£3.2M** |

*First contracts signed Q4 2027. Revenue recognized Q1 2028+ per NHS payment cycles.

**Break-even:** Year 3 (2028)

---

## ğŸ’· Use of Funds (Â£750k / 18 months)

| Category | Amount | Details |
|----------|--------|---------|
| **Team** | Â£360k | Founder/Engineer (Â£165k), Compliance Officer (Â£105k), Clinical Validation Lead (Â£90k) |
| **Regulatory** | Â£180k | UKCA certification (Â£100k), 4 NHS pilot studies (Â£80k) |
| **Infrastructure** | Â£210k | Cloud/AI compute (Â£15k), Legal (Â£25k), Insurance (Â£15k), Office (Â£20k), Marketing (Â£15k), Contingency 24% (Â£120k) |

### Key Milestones at 18 Months
âœ… UKCA certification complete  
âœ… 4 NHS pilot validations published  
âœ… First 2-3 contracts signed (Q4 2027)  
âœ… Series A ready

---

## ğŸ¯ Competitive Landscape

### Existing Solutions (Fragmented)
- **Lab Automation** (e.g., Scopio Labs): AI morphology onlyâ€”no genomic integration
- **Genomics Platforms** (e.g., SOPHiA GENETICS): Sequencing analysis onlyâ€”no automated diagnosis
- **AI Pathology** (e.g., PathAI): Solid tumor focusâ€”not built for haematology complexity

### Our Unique Position
âœ… **Integrated, not siloed** - First to fuse morphology, flow cytometry, and genomics  
âœ… **Built for 2022 guidelines** - Purpose-built for WHO & ICC 2022 mutation-based criteria  
âœ… **Diagnosis to decision** - Beyond classification: risk stratification + treatment guidance  
âœ… **Rapid deployment** - No IT integration required

---

## ğŸ›¡ï¸ Regulatory Strategy

### Classification
- **Device Type**: Class IIb medical device (diagnostic software with AI)
- **Pathway**: UKCA certification (UK), CE marking (EU), FDA clearance (US - future)

### Timeline
- **Q1 2026**: Engage notified body, submit technical file
- **Q2-Q3 2026**: Clinical evaluation, performance studies
- **Q4 2026-Q1 2027**: UKCA audit and certification
- **Budget**: Â£100k allocated

### Compliance
- ISO 13485 (Medical Device QMS)
- ISO 27001 (Information Security)
- UK GDPR compliant
- NHS Data Security and Protection Toolkit
- Cyber Essentials Plus

---

## ğŸŒ Expansion Strategy

### Geographic Expansion
1. **UK** (2026-2028): Proving ground, NHS contracts
2. **EU** (2028-2029): CE marking, private hospitals
3. **Middle East** (2028-2030): GCC countries (high healthcare spend)
4. **Asia** (2029-2031): Malaysia, Singapore (UK medical training ties)
5. **US** (2030+): FDA clearance, major market entry

### Product Expansion
1. **Now**: Acute Myeloid Leukemia (most complex)
2. **12-18 months**: All blood cancers (MDS, lymphomas, myeloma)
3. **24+ months**: Solid tumors and beyond

**Strategic approach:** Master the hardest problem first, then scale the framework.

---

## âš¡ Why Now?

1. **Technology convergence**: LLMs finally accurate enough for medical data extraction
2. **Guidelines complexity**: WHO 2022 and ICC 2022 just too complex for manual application
3. **NHS AI investment**: Â£20M AI Diagnostic Fund actively seeking solutions
4. **Market validation**: Our pilot trusts are desperate for this solution
5. **Regulatory clarity**: MHRA guidance on AI as medical device now clear

---

## ğŸ† Why Haem.io Will Win

1. **Unique Team**: Only team with practicing NHS haematologists + AI expertise
2. **Clinical Validation**: NHS pilots + Â£7M grant inclusion = credibility
3. **Technology Differentiation**: Hybrid AI + logic (transparent, explainable, certifiable)
4. **Zero Friction**: Works with any report formatâ€”no IT integration
5. **First Mover**: No direct competitors in end-to-end blood cancer diagnostics
6. **Massive Market**: Blood cancer â†’ all cancers as genomics become standard

---

## ğŸ“ Contact & Next Steps

**Robert Edward Lee**  
CEO & Founder, Haem.io  

ğŸ“§ Email: [your email]  
ğŸ“± Phone: [your phone]  
ğŸ”— LinkedIn: [your LinkedIn]  
ğŸŒ Website: https://haem.io

### Available Materials
- ğŸ“Š Full pitch deck (15 slides)
- ğŸ¥ Product demo video (3 minutes)
- ğŸ“ˆ Financial model (Excel)
- ğŸ“ Data room (technical docs, pilot agreements, letters of support)

### Immediate Ask
- **15-minute introductory call** to discuss opportunity and answer questions
- **Product demonstration** with clinical co-founders
- **Reference calls** with NHS pilot site clinicians

---

## ğŸ”’ Investment Terms (Indicative)

- **Amount**: Â£750,000
- **Valuation**: Â£3-4M pre-money
- **Equity**: 18-25%
- **Instrument**: SEIS/EIS qualifying (50% tax relief for UK investors)
- **Board seat**: 1 investor observer/director
- **Information rights**: Standard quarterly reporting
- **Pro-rata rights**: Standard for seed investors
- **Anti-dilution**: Standard broad-based weighted average

*Terms negotiable with the right partner. We're optimizing for strategic value, not just capital.*

---

## ğŸ¯ Investment Highlights Summary

âœ… **Problem**: Life-or-death diagnostic delays in blood cancers  
âœ… **Solution**: AI + logic engine for 2-minute diagnosis (vs. days/weeks)  
âœ… **Team**: 2 NHS haematologists + tech founders  
âœ… **Traction**: 3 NHS pilots + Â£7M grant inclusion  
âœ… **Market**: Â£30B AI diagnostics market, 1.2M annual blood cancer cases  
âœ… **Differentiation**: Only end-to-end solution, zero integration friction  
âœ… **Regulatory**: Clear UKCA pathway, Â£100k budgeted  
âœ… **Financials**: Break-even Year 3, Â£5.6M revenue Year 5  
âœ… **Vision**: Blood cancers first â†’ all cancers  

---

**Transforming cancer diagnosis through AI + clinical expertise**

*Last updated: November 7, 2025*

---

### Appendix: Key Questions Answered

**Q: Why can't hospitals just use ChatGPT?**  
A: Three reasons: (1) Regulatoryâ€”generic LLMs can't be certified as medical devices, (2) Liabilityâ€”no explainability or audit trail, (3) Accuracyâ€”we've tested this; generic LLMs fail on complex diagnostic pathways.

**Q: What if big tech builds this?**  
A: Three defensible moats: (1) Clinical expertiseâ€”our haematologist co-founders encode years of specialist knowledge, (2) NHS relationshipsâ€”we're building trust within NHS networks, (3) Speed to marketâ€”by the time big tech enters, we'll have contracts and regulatory approvals.

**Q: How do you compete with SOPHiA GENETICS?**  
A: Different problem. SOPHiA does genomic sequencing analysis (upstream). We do end-to-end diagnosis + treatment matching (downstream). Potentially complementary.

**Q: Why start with blood cancers?**  
A: Strategic choice: (1) Highest complexityâ€”if we solve this, all other cancers become easier, (2) Team expertiseâ€”our clinical co-founders are haematologists, (3) Market validationâ€”pilot trusts are already desperate for this solution, (4) Speed to valueâ€”blood cancer patients can't wait for diagnosis.

**Q: What's the biggest risk?**  
A: Regulatory delays. UKCA could take longer than planned. We've mitigated this by engaging notified body early, budgeting conservatively (Â£100k), and hiring a compliance officer. Our 24% contingency buffer provides additional runway if needed.

